Perry Shieh is a Neurology physician. OpenAlex indexes 231 publications with 10,552 citations (h-index 49); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Medical Plaza
#b200
Los Angeles, CA 900950001
Telephone
310-794-1195Provider last certified this registry record 16 Jan 2020.
Clinical trials
- Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
Sponsor: Catalyst Pharmaceuticals, Inc.
- Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome
Sponsor: Catalyst Pharmaceuticals, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
32 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Sarepta Therapeutics, Inc.Program year202554 payments$200,839openpaymentsdata.cms.gov ↗
- Alexion Pharmaceuticals, Inc.Program year2025177 payments$125,670openpaymentsdata.cms.gov ↗
- UCB, Inc.Program year2025130 payments$83,426openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2022–2023 per NIH RePORTER. The latest:
- Opto-Electrophysiological Method to Study Human Skeletal Muscle Channelopathies
University of California Los Angeles
FY2023$154,440R21AR080282 - Opto-Electrophysiological Method to Study Human Skeletal Muscle Channelopathies
University of California Los Angeles
FY2022$205,920R21AR080282
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry
Journal of Neuromuscular Diseases
2024 - Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)
Journal of Neuromuscular Diseases
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”